이재훈 교수 연구실
letter|
인용수 1
·2024
Long-term efficacy and safety of tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: final analysis of phase IIb results
Shinya Rai, Won Seog Kim, Kiyoshi Ando, Ilseung Choi, Koji Izutsu, Norifumi Tsukamoto, Dai Maruyama, Kunihiro Tsukasaki, Junya Kuroda, Jun Ando, Michihiro Hidaka, Youngil Koh, Hisashi Kato, Toshiki Uchida, Deok Hwan Yang, Kenji Ishitsuka, Kenichi Ishizawa, Jin Seok Kim, Mark Hong Lee, Hironobu Minami, Hyeon Seok Eom, Mitsutoshi Kurosawa, Jae Hoon Lee, Jong Seok Lee, Won Sik Lee, Hirokazu Nagai, Takero Shindo, Dok Hyun Yoon, Shinichiro Yoshida, Mireille Gillings, Hiroshi Onogi, Kensei Tobinai
IF 7.9Haematologica
초록
제공된 초록이 없습니다.
*본 초록은 AI를 통해 원문을 번역한 내용입니다. 정확한 내용은 하기 원문에서 확인해주세요.
키워드
Refractory (planetary science)MedicineLymphomaOncologyInternal medicineTerm (time)Peripheral T-cell lymphomaPeripheralSurgeryT cell